Cardium Therapeutics utilizes a growth strategy based on acquisition of businesses with the potential to address unmet medical needs. The company’s investment portfolio includes the Tissue Repair Company; Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing and cardiovascular indications; and the MedPodium healthy lifestyle product platform. Cardium’s acquisition strategy is executed under the guidance of an eight-member team with decades of combined experience spanning the healthcare sector.
Between the two of them, Cardium Therapeutics co-founders Christopher J.Reinhard and Dr. Tyler M. Dylan-Hyde (Ph.D., J.D.) have experience working for numerous biotech companies, an industrial and manufacturing group, and in the development of biologics and devices for cardiovascular and ischemic diseases, among others. Reinhard has served as chairman of the board, CEO, president, and treasurer since the company’s inception in December 2003. Dr. Dylan-Hyde is Cardium’s director, chief business officer, general counsel, executive vice president, and secretary, as well as company co-founder.
Heading the company’s fiscal responsibilities is Cardium Therapeutics CFO Dennis M. Mulroy, CPA, who joined the company in November 2005. In addition to his roles with several company subsidiaries, he was also previously appointed CFO of three publicly traded biotech companies not affiliated with Cardium Therapeutics. Additionally, Mulroy was employed with Ernst & Young in San Diego, Calif.
Dr. Gabor M. Rubanyi, (M.D., Ph.D.), is Cardium Therapeutics chief scientific officer. Before taking the position in June 2006, Dr. Rubanyi provided consulting services to the company. Prior to that, he served various companies as vice president, adjunct professor, and associate professor. Dr. Rubanyi is the author or co-author of 22 books and more than 325 research articles. He serves as an editorial board member to several biomedical journals and is the founder of biomed journal Endothelium.
Determining the value of a potential acquisition target takes business savvy and experience. Cardium Therapeutics is backed by Mark McCutchen, who is vice president of business development for both Cardium Therapeutics and Tissue Repair Company. He has more than 15 years of financial and business management experience in the life sciences industry and has overseen seven rounds of venture and private financings totaling more than $60 million. Among other achievements, he also has experience in equity and debt transactions for high technology and life science companies.
Also integral to seeking out acquisitions in the healthcare sector is hands-on knowledge of the medical field itself. Dr. Robert L. Engler serves as Cardium Therapeutics’ chief medical advisor and was the co-founder of Collateral Therapeutics, where he was a director, vice president, and medical director at various stages. He is also professor of Medicine Emeritus at the University of California, San Diego. Among other previous endeavors, Dr. Engler was a clinical cardiologist and associate chief of staff for research and development at the Veterans’ Affairs Medical Center. He is director of publicly traded biotech company, Halozyme Therapeutics.
Cardium Therapeutics’ management team comprises every aspect of the healthcare sector, including regulations. Ted Williams is the vice president of Cardium Therapeutics’ manufacturing and technical operations, where he lends his more than 25 years of professional experience in FDA-regulated environments of biopharm process development, medical device development, quality control/quality assurance, and more. He also serves as vice president of Tissue Repair’s manufacturing and technical operations, and held the same position at InnerCool Therapies until its sale to Royal Philips Electronics in July 2009. Prior to joining Cardium Therapeutics, Williams held various roles, including director of research operations, process technologies, and quality systems; senior manager of quality systems; manager of quality control; supervisor of quality control; and chief microbiologist and supervisor.
Dr. Lois A. Chandler, vice president of biologics development for Cardium Therapeutics, has 17 years of professional experience in biopharmaceutical design and clinical development, chemistry, manufacturing and controls, quality control, and custom DNA vector design. She has also served as associate director of vector development for a company that developed targeted viral and non-viral DNA therapeutics for dermal, cardiovascular, and orthopedic tissue repair; as a senior scientist of molecular biology.
Backed by a seasoned and diverse management team, the company looks forward to achieving its goals for 2012, which include its plans to advance commercialization of its new Excellagen® advanced, physician-use wound care product through strategic partners in the U.S. and internationally; develop new product extensions based on Excellagen’s formulated collagen product platform for additional wound healing applications; advance its ASPIRE Generx® clinical study at leading medical centers in the Russian Federation for patients with advanced coronary disease; introduce additional product line extensions and broaden national distribution of the company’s MedPodium® healthy lifestyle product platform; and continue to identify and evaluate businesses, product opportunities and technologies complementary with Cardium Therapeutics’ long-term business, and acquisition strategy.
To learn more about the company, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
